tbuckley/cabot-search huggingface dataset:
Abstract 13513: MitraClip <sup>®</sup> for Functional Mitral Regurgitation: Outcomes in Over 600 Patients
Authors: Gorav Ailawadi, D. Scott Lim, Irving L Kron, Alfredo Trento, Saibal Kar, Michael J Mack, Paul Grayburn, Donald D Glower, Andrew Wang, Elyse Foster, Neil J Weissmann, Paul Pearson, Ted Feldman
Journal: Circulation (2015)

Background: The treatment options for degenerative or primary mitral regurgitation (DMR) include mitral surgery and transcatheter edge-to-edge repair (MitraClip). However, the optimal therapy for patients with functional or secondary MR (FMR) remains unclear. The purpose of this study was to evaluate the 1 year outcomes of all patients with FMR undergoing MitraClip in the United States as part of the EVEREST (Endovascular Valve Edge-to-Edge Repair STudy) II study. Methods: Patients treated in the EVEREST II trial (randomized trial and continued access registries) with severe FMR were evaluated. Outcomes at 30 days and 1 year were analyzed and adjudicated by an independent core laboratory. Patients were further stratified by surgical risk (High risk= STS mortality score ≥12% or pre-specified risk factors). Results: A total of 619 patients (mean age=73.4 years) with FMR were treated with MitraClip. Comorbidities were common including coronary artery disease (81.1%), NYHA functional class III/IV (80.3%), and previous coronary artery bypass grafting (55.7%). Device implantation was achieved in 96.4% with a mean hospital stay of 3.3 days and an 87.2% discharge to home. At 30 days, mortality was 3.6% with a major adverse event rate of 9.2%. At 1 year, the survival was 78.3%, while the majority of survivors had MR≤2+ (84.5%) and significantly improved symptoms (83.2% NYHA Class I/II). The left ventricular end diastolic volume (LVEDV) improved from 162.5ml to 152.6ml (P&lt;.001). When comparing high surgical risk patients (n=485; mean STS score=10.6±6.9%) to non-high risk patients (n=134), the 30 day mortality was similar (4.1% vs. 1.5%, P=.19), but the 1 year mortality was worse (22.7% vs. 13.4%, P=.02). Nevertheless, at 1 year, there were similar rates of MR reduction (MR≤2+: 83.9% vs. 87.3%) and improvement in LVEDV (-9.0ml vs -12.6ml). The non-high risk cases had greater symptom improvement (NYHA Class I/II: 91.2% vs. 80.2%, P=.001). Conclusions: MitraClip in patients with severe FMR is associated with excellent safety, positive ventricular remodeling, symptom improvement, and stable MR reduction at 1 year independent of surgical risk. Compared to high surgical risk patients, non-high risk patients may derive the greatest survival and symptom benefit.
Brain imaging tests for chronic pain: medical, legal and ethical issues and recommendations
Authors: Karen D. Davis, Herta Flor, Henry T. Greely, Gian Domenico Iannetti, Sean Mackey, Markus Ploner, Amanda Pustilnik, Irene Tracey, Rolf-Detlef Treede, Tor D. Wager
Journal: Nature Reviews Neurology (2017)

Chronic pain is the greatest source of disability globally and claims related to chronic pain feature in many insurance and medico-legal cases. In this Consensus Statement, a presidential task force of the International Association for the Study of Pain examines the capabilities of brain imaging in the diagnosis of chronic pain, and the ethical and legal implications of such uses of brain imaging. Chronic pain is the greatest source of disability globally and claims related to chronic pain feature in many insurance and medico-legal cases. Brain imaging (for example, functional MRI, PET, EEG and magnetoencephalography) is widely considered to have potential for diagnosis, prognostication, and prediction of treatment outcome in patients with chronic pain. In this Consensus Statement, a presidential task force of the International Association for the Study of Pain examines the capabilities of brain imaging in the diagnosis of chronic pain, and the ethical and legal implications of its use in this way. The task force emphasizes that the use of brain imaging in this context is in a discovery phase, but has the potential to increase our understanding of the neural underpinnings of chronic pain, inform the development of therapeutic agents, and predict treatment outcomes for use in personalized pain management. The task force proposes standards of evidence that must be satisfied before any brain imaging measure can be considered suitable for clinical or legal purposes. The admissibility of such evidence in legal cases also strongly depends on laws that vary between jurisdictions. For these reasons, the task force concludes that the use of brain imaging findings to support or dispute a claim of chronic pain — effectively as a pain lie detector — is not warranted, but that imaging should be used to further our understanding of the mechanisms underlying pain.
Tele-Operating an Android Robot to Promote the Understanding of Facial Expressions and to Increase Facial Expressivity in Individuals With Autism Spectrum Disorder
Authors: Hirokazu Kumazaki, Taro Muramatsu, Yuichiro Yoshikawa, Yoshio Matsumoto, Masutomo Miyao, Hiroshi Ishiguro, Masaru Mimura, Yoshio Minabe, Mitsuru Kikuchi
Journal: American Journal of Psychiatry (2017)
Neutrophil to lymphocyte ratio as predictive of prolonged progression free survival (PFS) and overall survival (OS) in patients with metastatic non-small cell lung cancer (NSCLC) treated with second-line PD-1 immune checkpoint inhibitors.
Authors: Stephanie Labomascus, Ibtihaj Fughhi, Philip Bonomi, Mary J. Fidler, Jeffrey Allen Borgia, Sanjib Basu, Matthew A Hoch, Marta Batus
Journal: Journal of Clinical Oncology (2017)

e14530 Background: Baselinehigh neutrophil to lymphocyte ratio (NLR) has been associated with inferior overall survival in patients with stage III/IV NSCLC. Inflammation and neutrophilic infiltrates in the tumor microenvironment appear to inhibit anti-tumor immune response. We suspect that NLR might reflect the level of inflammation in tumor microenvironment. The objectives of this study were to evaluate potential relationships between pretreatment NLR and and PFS and OS in advanced NSCLC patients treated with second-line nivolumab or pembrolizumab. Methods: Patients with stage IV NSCLC who received at least one cycle of nivolumab or pembrolizumab after first-line treatment with a platinum doublet between January 2015 and December 2016 were included. Patient demographics including NLR at baseline, date of starting immunotherapy, and date of progression were recorded. The association between NLR and duration of response was assessed using a Mann-Whitney-Wilcoxon test. A cutoff of NLR of 3.5 and 5.0 based on published data (ref) were analyzed for differences in median overall survival and progression free survival. Results: 113 patients were analyzed: median age 68, male/female 38.9%/61.1%, 15% never smoked. The median PFS for patients with NLR &lt; 5 was 4.14 months vs. 2.27 months in those with NLR &gt; 5 (p = 0.031). Overall survival was also impacted by NLR. There were a total of 29 deaths in the cohort, 24 of these occurred in patients with NLR &gt; 3.5 and 5 were in patients with NLR &lt; 3.5. A lower NLR at baseline was significantly associated with improved overall survival (p = 0.036). Conclusions: A low baseline NLR is associated with superior progression free survival and overall survival in metastatic non-small cell lung cancer patients treated with nivolumab or pembrolizumab. These findings suggest that evaluating mediators of inflammation might help to identify potential therapeutic targets which could enhance effectiveness of PD-1 immune check point inhibitors in advanced NSCLC.
Updated survival of patients (pts) with previously treated <i>BRAF</i> V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.
Authors: David Planchard, Benjamin Besse, Tae Min Kim, Elisabeth A. Quoix, Pierre Jean Souquet, Julien Mazieres, Fabrice Barlesi, Harry J.M. Groen, Egbert F. Smit, Christina S. Baik, Byoung Chul Cho, Ronan Joseph Kelly, Mark A. Socinski, Silvia Novello, James R. Rigas, Vanessa Giannone, Anthony Michael D'amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E. Johnson
Journal: Journal of Clinical Oncology (2017)

9075 Background: BRAF V600E mutations occur in 1% to 2% of lung adenocarcinomas and act as oncogenic drivers. Initial cohorts of the BRF113928 (NCT01336634) trial evaluated efficacy and safety of D monotherapy (cohort A; n = 78) or D + T (cohort B; n = 57) in pts with previously treated BRAFV600E–mutant metastatic NSCLC. At primary analysis, overall response rates (ORRs) were 33.3% and 63.2% in pts who received D or D + T, respectively. Furthermore, durable response (median duration of response [DOR], 9.0 mo) was observed in D + T pts. Here, we present an updated survival analysis based on additional follow-up. Methods: In this phase 2 trial, 2 cohorts (A and B) of pts with previously treated metastatic BRAFV600E–mutant NSCLC were enrolled sequentially. The primary endpoint was investigator-assessed ORR. Secondary efficacy endpoints included progression-free survival (PFS), DOR, and overall survival (OS). D and T were dosed orally at the established phase 2 dose of D 150 mg twice daily and T 2 mg once daily. Results: This updated analysis had a median follow-up of 16.2 mo, which represented an additional 10 mo of follow-up. Median OS was 12.7 mo (95% CI, 7.3-16.3) with 57 deaths reported for pts treated with D monotherapy and 18.2 mo (95% CI, 14.3-not estimable [NE]) with 33 deaths reported for pts treated with D + T. Detailed efficacy results are presented in the table. Investigator-assessed ORR, DOR, and PFS were supported by independent review committee assessments. No new safety signals were observed for D + T. Conclusions: This update of the BRF113928 study confirms that durable responses and encouraging survival were achieved with combination D + T in pts with BRAFV600E–mutant NSCLC. Clinical trial information: NCT01336634. [Table: see text]
10,000 Steps Australia: a community-wide eHealth physical activity promotion programme
Authors: Mitch J Duncan, Wendy J Brown, W Kerry Mummery, Corneel Vandelanotte
Journal: British Journal of Sports Medicine (2017)

The programme originated from a landmark whole-of-community multistrategy intervention designed to increase adult physical activity in the regional city of Rockhampton, Australian in 2001–2003.1 The project used a social ecological framework, focusing on strategies that promoted physical activity at the individual, population, environmental and policy level. The two fundamental aspects of the programme are1: goal setting (10 000 steps per day) and2 self-monitoring (the use of a pedometer to track daily step counts). A project website (www.10000steps.org.au) allowed members to record their physical activity, and provided a platform for dissemination of project resources to workplaces and community groups.2 3 

### The message is simple and clear

The project name, with its distinctive logo (Figure 1) and tagline (‘every step counts’) provide a clear and prescriptive target for the physical activity ‘dose’.1 4 The intervention encourages participants to establish their baseline daily steps, and gradually increase activity to achieve the 10 000 steps a day target. Considerable evidence supports the use of …
Assessment of clinical symptoms in household contacts of confirmed pertussis cases
Authors: Angela Domínguez, Núria Soldevila, Joan A. Caylà, Manuel García-Cenoz, Glòria Ferrús, Maria Rosa Sala-Farré, Josep Álvarez, Mònica Carol, Irene Barrabeig, Neus Camps, Lorena Coronas, Carmen Muñoz-Almagro, Pere Godoy, Miquel Alsedà, Josep Álvarez, César Arias-Varela, Irene Barrabeig, Neus Camps, Glòria Carmona, Mónica Carol, Maria Company, Joaquim Ferràs, Glòria Ferrús, Mireia Jané, Sofia Minguell, Raquel Rodríguez, María-Rosa Sala-Farré, Roser Torra, Pere Godoy, Pedro Plans, Inma Crespo, Diana Toledo, Àngela Domínguez, Rubén Solano, Lorena Coronas, Joan Caylà, Sara Lafuente, None Cristina Rius, Manuel García-Cenoz, Rosana Burgui, Jesús Castilla, Ana Valero-Rello, Iolanda Jordan, Carmen Muñoz-Almagro
Journal: Journal of Infection (2017)
Preimplantation Genetic Diagnosis for Mendelian Conditions
Authors: Siobhan M. Dolan, Tamar H. Goldwaser, Sangita K. Jindal
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage
Authors: Nidhi Tandon, Surbhi Sidana, Angela Dispenzieri, Morie A. Gertz, Francis K Buadi, Martha Q. Lacy, David Dingli, Amie Fonder, Suzanne R. Hayman, Miriam Hobbs, Prashant Kapoor, Wilson I Gonsalves, Yi L. Hwa, Robert A. Kyle, Ronald S. Go, John A Lust, Nelson Leung, Stephen J. Russell, Steven R. Zeldenrust, S. Vincent Rajkumar, Shaji Kumar
Journal: Blood (2016)
Redefining Unexplained Anemia in Elderly
Authors: Michele F. Eisenga, Suzanne P. Stam, Stephan J. L. Bakker
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): The CLARINET extension study.
Authors: Edward M. Wolin, Marianne Pavel, Jaroslaw B Cwikla, Alexandria T. Phan, Markus Raderer, Eva Sedlackova, Guillaume Cadiot, Jaume Capdevila, Lucy Wall, Guido Rindi, Catherine Lombard-Bohas, Nilani Liyanage, Xuan Mai Truong Thanh, Philippe Ruszniewski, Martyn E. Caplin
Journal: Journal of Clinical Oncology (2017)

4089 Background: In the CLARINET core study, lanreotide Autogel (LAN) 120 mg deep sc monthly significantly improved PFS vs PBO in metastatic grade-1/2 enteropancreatic NETs. An interim analysis of patients with stable disease (SD) in the core study continuing LAN in the open-label extension (OLE, of which safety was primary objective) showed continued antitumor effects. Here, we report final LAN PFS analyses for subgroups according to tumor origin and prior therapy. Methods: In the core study, patients with metastatic well/moderately differentiated non-functioning (N-F) enteropancreatic NETs, Ki-67 &lt;10%, no prior somatostatin-analog treatment and no other prior medical therapies in the previous 6 months were randomized to LAN 120 mg (n=101) or PBO (n=103) for 96 weeks or until death/progressive disease (PD; RECIST 1.0). Patients with SD receiving LAN and any patient receiving PBO could enter a single-arm (LAN) OLE (NCT00842348). Main efficacy endpoint: PFS (time from core-study randomization to death/PD) for core-study intent-to-treat population from Kaplan–Meier survival analysis. Here, PFS was analyzed in subgroups of LAN–LAN patients. Results: OLE final population comprised 89 patients (LAN–LAN 42 [41 with SD]; PBO–LAN 47 [15 with SD]); 38% had pancreatic and 38% midgut NETs. During the OLE, 40% continuing LAN vs 47% switched to LAN had treatment-related adverse events. No new safety concerns were identified. Overall LAN median PFS from the LAN–LAN group was 38.5 months, and varied with tumor origin and prior therapy (Table). Conclusions: CLARINET OLE suggests sustained antitumor effects with LAN 120 mg in enteropancreatic NETs irrespective of tumor origin, and suggests benefits with LAN as early treatment. Clinical trial information: NCT00842348. [Table: see text]
THU0258 Serum paraoxonase 3 levels are decreased and paraoxonase 3 activity is reduced in patients with systemic lupus erythematosus as compared to healthy controls
Authors: A Dhooria, K Priyanka, A Sharma, I Verma, A Lal, S Singh
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Premature atherosclerosis is a well recognised comorbidity in patients with SLE (1). Elevated levels of circulating Oxidised Low Density Lipoprotein (OxLDL) have been described in SLE patients, especially in those with a history of cardiovascular disease (2). Paraoxonase 3 (PON 3) is believed to play a role in prevention of atherosclerosis by contributing towards the anti oxidant actions of high density lipoprotein (HDL). <h3>Objectives</h3> To determine serum PON3 levels and PON 3 activity in patients with SLE and compare them with healthy controls. <h3>Methods</h3> Serum PON 3 levels and PON3 activity were determined in 100 patients of SLE with no prior history of coronary artery disease and they were compared with those of 50 healthy controls who did not have diabetes, hypertension or coronary artery disease. Serum PON3 concentration was determined by enzyme-linked immunosorbent assay (ELISA) using anti-PON3 antibody specific for human PON3. PON 3 activity was estimated using Spectrophotometric assay which quantified the hydrolysis of dihydrocoumarin at 270 nm (3). <h3>Results</h3> PON 3 levels were lower in SLE patients (P&lt;0.001) and PON 3 activity was reduced (p&lt;0.001) as compared to healthy controls. In subgroup analysis of SLE patients, PON 3 activity and levels did not correlate with disease activity. On Univariate analysis, serum creatinine (r<sup>2</sup>=0.06, p&lt;0.002), age (r<sup>2</sup>=0.03, p=0.035), and SLE status (r<sup>2</sup>=0.27, p&lt;0.001) contributed to PON3 levels. On Univariate analysis, serum creatinine (r<sup>2</sup>=0.15, p&lt;0.001), AST (r<sup>2</sup>=0.04, p=0.01), ALT (r<sup>2</sup>=0.16, p&lt;0.001) and SLE status (r<sup>2</sup>=0.77, p&lt;0.001) contributed to PON3 levels. On multivariate analysis, only SLE status predicted PON 3 levels (P&lt;0.001) and PON 3 activity (p&lt;0.001). <h3>Conclusions</h3> PON3 levels are reduced and PON 3 activity is decreased in patients with SLE as compared to healthy controls, the difference was attributable to the disease itself. This may contribute to premature atherosclerosis in these patients. <h3>References</h3> Nikpour M, Urowitz MB, Gladman DD. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am. 2005;31:329–54. Frostegard J, Svenungsson E, Wu R et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum. 2005;52:192–200. Draganov DI, Teiber JF, Speelman A et al. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005;46:1239–47. <h3>Acknowledgements</h3> None. <h3>Disclosure of Interest</h3> None declared
The targeted cytotoxic prodrug, AQ4N, persists in the spleen, large intestine, and subcutaneous tumors
Authors: Jeffrey L. Cleland, Alvin Wong, Susan E. Alters
Journal: Cancer Research (2005)

2410   AQ4N (banoxantrone; 1,4 bis[[2-(dimethylamino)ethylamino}-5,8-hydroxyanthracene-9,10-dione bis N-oxide) is a targeted cytotoxic prodrug that is bioreduced to AQ4, a highly potent DNA topoisomerase II inhibitor. AQ4N is transported to the cytoplasm of cells and then enzymatically bioreduced under conditions of low oxygen providing a reservoir of cytotoxic drug that kills hypoxic tumor cells when they proliferate. The biodistribution and tumor retention of AQ4N was assessed in a pancreatic xenograft tumor mouse model (BXPC-3) in two studies: 1) AQ4N  14 C labeled in the benzene ring; 2) AQ4N  14 C labeled on the methyl groups of the tertiary amine. Differential exposure to these two radiolabelled forms allows assessment of AQ4N metabolism. SCID mice (∼50 total per study) were implanted subcutaneously (SC) with BXxPC-3 tumor cells (10 6  cells) and treated after tumors were 100-200 mm 3 . All mice except 3 controls were IV administered 20 mg/kg AQ4N (120 μCi/kg). Mice per time point were sacrificed at time points (3 mice/time) up to 14 days post dose. Control mice plasma with spiked with radiolabelled AQ4N was used to generate a standard curve for assessing radioactivity in tissue extracts and plasma. The greatest differential exposure to AQ4N radioactivity occurred in the liver and kidney. Liver and kidney toxicity has not been observed in animals or humans and the lower exposure of the methyl labelled AQ4N suggests metabolism of AQ4N in these tissues. In cases of consistent exposure, toxicity was observed in the form of minor spleenic atrophy and mild gastrointestinal toxicity. Significant sustained levels of radioactivity were also observed in the brain and pancreas for both studies. While AQ4N radioactivity was rapidly cleared from the plasma, AQ4N radioactivity in tumors persisted for 14 days. The tumor persistence of AQ4N may be the mechanism for AQ4N efficacy observed in the BXPC-3 xenograft tumor model. Overall, a differential accumulation of an intact AQ4N species in the spleen and large intestine was observed along with tumor persistence. To further evaluate the metabolism of AQ4N, a study is underway to perform tissue extraction and analysis.
高分子C型肝炎ウイルス非構造蛋白質5Aナノカプセルは肝内抗原特異的免疫反応を誘導する【Powered by NICT】
Authors: Fichter Michael, Piradashvili Keti, Pietrzak-Nguyen Anette, Pretsch Leah, Kuhn Gabor, Strand Susanne, Knuf Markus, Zepp Fred, R Wurm Frederik, Mailaender Volker, Landfester Katharina, Gehring Stephan
Journal: Biomaterials (2016)
Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis
Authors: Ankana Daga, Amar J. Majmundar, Daniela A. Braun, Heon Yung Gee, Jennifer A. Lawson, Shirlee Shril, Tilman Jobst-Schwan, Asaf Vivante, David Schapiro, Weizhen Tan, Jillian K. Warejko, Eugen Widmeier, Caleb P. Nelson, Hanan M. Fathy, Zoran Gucev, Neveen A. Soliman, Seema Hashmi, Jan Halbritter, Margarita Halty, Jameela A. Kari, Sherif El-Desoky, Michael A. Ferguson, Michael J.G. Somers, Avram Z. Traum, Deborah R. Stein, Ghaleb H. Daouk, Nancy M. Rodig, Avi Katz, Christian Hanna, Andrew L. Schwaderer, John A. Sayer, Ari J. Wassner, Shrikant Mane, Richard P. Lifton, Danko Milosevic, Velibor Tasic, Michelle A. Baum, Friedhelm Hildebrandt
Journal: Kidney International (2017)